ZIOP - ZIOPHARM Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.2300
-0.1300 (-3.87%)
At close: 4:00PM EST

3.2100 -0.02 (-0.62%)
After hours: 4:35PM EST

Stock chart is not supported by your current browser
Previous Close3.3600
Open3.3800
Bid3.2100 x 3000
Ask3.2500 x 2900
Day's Range3.1900 - 3.3900
52 Week Range2.5500 - 7.2500
Volume1,239,435
Avg. Volume2,069,190
Market Cap569.249M
Beta (5Y Monthly)2.99
PE Ratio (TTM)5.62
EPS (TTM)0.5750
Earnings DateMar 01, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.30
  • GlobeNewswire

    Ziopharm Oncology Announces Pricing of Public Offering of Common Stock

    Ziopharm Oncology, Inc. (ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public offering price of $3.25 per share. Ziopharm has granted the underwriters a 30-day option to purchase up to an additional 4,173,912 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds to Ziopharm before deducting underwriting discounts and commissions and estimated offering expenses payable by Ziopharm, are expected to be approximately $90.4 million, excluding any exercise of the underwriters’ option to purchase additional shares.

  • Benzinga

    The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 4) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...

  • GlobeNewswire

    Ziopharm Oncology Announces Proposed Public Offering of Common Stock

    Ziopharm Oncology, Inc. (ZIOP) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Ziopharm. Ziopharm also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the number of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions.

  • GlobeNewswire

    Ziopharm Oncology Announces Recent Publications in Peer-Reviewed Scientific Journals

    Ziopharm Oncology, Inc. (ZIOP), today announced two publications in peer-reviewed scientific journals supporting the Company’s ongoing clinical programs by reinforcing two of the foundational technologies underlying the Company’s approach to the genetic modification of T cells to target cancer. A paper in the journal Blood enhances the clinical data set surrounding the Sleeping Beauty platform by indicating encouraging long-term survival of patients that received CAR-T. The Clinical Cancer Research publication demonstrates that T-cell receptors (TCRs) targeting genetic changes within TP53 can be obtained from T cells in the peripheral blood, overcoming the need to harvest a patient’s tumor. The Company plans to expand its existing library of TCRs as part of its commitment to advance clinical development for the treatment of patients whose solid tumors have driver mutations, including in TP53, using Sleeping Beauty-modified T cells.

  • Options Traders Expect Huge Moves in ZIOPHARM Oncology (ZIOP) Stock
    Zacks

    Options Traders Expect Huge Moves in ZIOPHARM Oncology (ZIOP) Stock

    Investors need to pay close attention to ZIOPHARM Oncology (ZIOP) stock based on the movements in the options market lately.

  • GlobeNewswire

    Ziopharm Oncology Presentation at the 38th Annual J.P. Morgan Healthcare Conference to be Webcast

    BOSTON, Dec. 19, 2019 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a.

  • Hedge Funds Have Never Been This Bullish On ZIOPHARM Oncology Inc. (ZIOP)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On ZIOPHARM Oncology Inc. (ZIOP)

    Is ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their […]

  • GlobeNewswire

    Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares of Ziopharm’s common stock effective November 21, 2019. The options were granted as an inducement material to such employee’s entering into employment with Ziopharm in accordance with Nasdaq Listing Rule 5635(c)(4). The option has an exercise price of $4.59 per share, the closing price of the Company’s common stock on November 21, 2019.

  • GlobeNewswire

    Ziopharm Oncology Presents Pre-Clinical Data Validating “Rapid Personalized Manufacture” (RPM) with TCR at the 2019 American Society for Hematology Annual Meeting

    Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (ZIOP), today announced the presentation of pre-clinical data of Rapid Personalized Manufacture (RPM), in the “Adoptive Immunotherapy: Mechanisms and New Approaches” session at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando. “These pre-clinical data demonstrate that T cells genetically modified using DNA plasmids from the Sleeping Beauty system to express TCR with membrane bound IL-15 (mbIL15) exhibit anti-tumor effects,” said Drew Deniger, Ph.D., leader of Ziopharm’s TCR program.

  • Benzinga

    12 Biotech Stocks Primed For A Short Squeeze

    Biotech investment is fraught with risk. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts. These binary events , however, provide an opportunity for making ...

  • GlobeNewswire

    Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

    Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (ZIOP), today announced the presentation of new interim analyses of clinical data from two ongoing substudies in its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in combination with a PD-1 inhibitor, for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults, at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting in Phoenix.

  • Thomson Reuters StreetEvents

    Edited Transcript of ZIOP earnings conference call or presentation 7-Nov-19 9:30pm GMT

    Q3 2019 ZIOPHARM Oncology Inc Earnings Call

  • GlobeNewswire

    Ziopharm Oncology Updates Presentation and Webcast Time at the Jefferies 2019 London Healthcare Conference

    BOSTON, Nov. 18, 2019 -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) today announced that the Company’s presentation at the Jefferies 2019 London Healthcare Conference on November.

  • GlobeNewswire

    Ziopharm Oncology Presentation at the Jefferies 2019 London Healthcare Conference to be Webcast

    BOSTON, Nov. 11, 2019 -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a.

  • GlobeNewswire

    Ziopharm Oncology Reports Third Quarter 2019 Financial Results

    – Phase 2 trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors initiated at the National Cancer Institute (NCI) – – New agreement with MD.

  • GlobeNewswire

    Ziopharm Oncology to Host Conference Call to Discuss Third Quarter 2019 Results on November 7, 2019

    BOSTON, Oct. 30, 2019 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Thursday, November 7, at 4:30 p.m. ET.

  • Hedge Funds Have Never Been More Bullish On ZIOPHARM Oncology Inc. (ZIOP)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On ZIOPHARM Oncology Inc. (ZIOP)

    Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […]

  • GlobeNewswire

    Ziopharm Oncology and MD Anderson Cancer Center Announce New R&D Agreement to Expand TCR-T Program

    Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP), and The University of Texas MD Anderson Cancer Center today announced a new research and development agreement relating to Ziopharm’s Sleeping Beauty immunotherapy program to use non-viral gene transfer to stably express and clinically evaluate neoantigen-specific T-cell receptors (TCRs) in T cells (referred to as TCR-T). “We are delighted to deepen our relationship with MD Anderson, which provides treatment to a large and diverse population of cancer patients with solid tumors,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm.

  • MoneyShow

    Ziopharm Tests "Sleeping Beauty" for Oncology Treatment

    Ziopharm Oncology (ZIOP) recently announced that the FDA has cleared an investigational new drug application (IND) for a Phase I trial to test their 3rd generation CD19-specific CAR-T, explains biotech sector specialist John McCamant, editor of The Medical Technology Stock Letter.

  • GlobeNewswire

    Ziopharm Oncology Names Drug Development Leader Dr. Chris Bowden to Board of Directors

    Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP), today announced that Chris Bowden, M.D., an oncology drug development executive with more than 20 years leadership experience spanning pre-clinical development through commercialization, including the approval of several cancer medicines, has been appointed to the Company’s Board of Directors.  Dr. Bowden is the Chief Medical Officer of Agios Pharmaceuticals and was previously Vice President, Product Development Oncology, at Genentech, Inc., a member of the Roche Group. “We are delighted to welcome Dr. Bowden to the Ziopharm Board.

  • Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment
    Zacks

    Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment

    Jazz (JAZZ) enrolls first patient in a mid-stage study to evaluate defibrotide in prevention of neurotoxicity in relapsed/refractory DLBCL patients receiving CAR T-cell therapy.

  • GlobeNewswire

    Ziopharm Oncology Announces FDA Clearance of IND for Rapid Personalized Manufacture of CD19-specific CAR-T

    Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application (IND) for a phase 1 clinical trial to evaluate CD19-specific CAR-T, produced using a process termed rapid personalized manufacture (RPM), as an investigational treatment for patients with relapsed CD19+ leukemias and lymphomas. The IND clearance builds upon the Company’s experience with two prior generations of immunotherapy trials using the Sleeping Beauty platform, which it believes is the most clinically-advanced non-viral approach to the genetic modification of T cells.

  • MDNA.TO: Increased Overall Survival in rGBM Patients Seen with High Dose MDNA55…
    Zacks Small Cap Research

    MDNA.TO: Increased Overall Survival in rGBM Patients Seen with High Dose MDNA55…

    By David Bautz, PhD TSX:MDNA.TO READ THE FULL MDNA.TO RESEARCH REPORT Business Update Updated Data from Phase 2b Trial Presented at Targeting Innate Immunity Congress On September 25, 2019, Medicenna Therapeutics Corp. (TSX:MDNA) announced the presentation of updated clinical data from the ongoing Phase 2b trial of MDNA55, an IL-4 targeted toxin,

  • GlobeNewswire

    Ziopharm Oncology to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

    BOSTON, Aug. 28, 2019 -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, will participate in a.